In today’s business landscape, CSR reporting has emerged as a vital component of business operations, reflecting a growing emphasis on transparency and responsibility. This research aims to examine the possible financial benefits of CSR reporting in Indian pharmaceutical firms. CSR disclosures were evaluated by content analysis of business sustainability reports, and financial data were sourced from NIFTY Pharma companies. The research used the Generalized Method of Moments (GMM) model to address potential endogeneity, autocorrelation, and heteroscedasticity in the panel data. The study shows that CSRD does not significantly affect ROA and ROE, indicating a minimal effect on the efficiency of assets and shareholder returns. However, CSRD has a significant negative impact on PAT, indicating that CSR-related expenditures reduce net profits in the long term. The results were aligned with Slack Resource Theory, Stakeholder Theory, Institutional Theory, Agency Theory, and Signalling Theory. Companies may use the findings to effectively integrate CSR into their business plan. CSR mandates make Indian pharmaceutical companies more appealing to environmentally and socially conscious investors. Pharmaceutical companies may enhance public trust and brand recognition via CSR disclosure